

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Enzalutamide

March 17, 2026

Therapeutic category

Other antitumor agents

Non-proprietary name

Enzalutamide

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.
 This English version is intended to be a reference material to provide convenience for users.
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current			Revision		
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) Patients receiving doravirine, ensitrelvir fumaric acid, lenacapavir sodium, <u>or</u> nirmatrelvir/ritonavir			2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) Patients receiving doravirine, ensitrelvir fumaric acid, lenacapavir sodium, nirmatrelvir/ritonavir, <u>elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate, darunavir ethanolate/cobicistat, darunavir ethanolate/cobicistat/emtricitabine/tenofovir alafenamide fumarate, dolutegravir sodium/rilpivirine hydrochloride, bictegravir sodium/emtricitabine/tenofovir alafenamide fumarate, rilpivirine, rilpivirine hydrochloride, or rilpivirine hydrochloride/emtricitabine/tenofovir alafenamide fumarate</u>		
10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following.)			10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following.)		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
Doravirine Ensitrelvir fumaric acid Lenacapavir sodium Nirmatrelvir/ritonavir	The effects of these drugs may be attenuated by coadministration with enzalutamide.	The CYP3A4-inducing activity of enzalutamide may lead to a decrease in the	Doravirine Ensitrelvir fumaric acid Lenacapavir sodium Nirmatrelvir/ritonavir <u>Elvitegravir/cobicistat/</u>	The effects of these <u>antiviral</u> drugs may be attenuated by coadministration with enzalutamide.	The CYP3A4-inducing activity of enzalutamide may lead to a decrease in the

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

		blood concentration of these drugs.	<u>emtricitabine/tenofovir</u> <u>alafenamide fumarate</u> <u>Darunavir</u> <u>ethanolate/cobicistat</u> <u>Darunavir</u> <u>ethanolate/cobicistat/</u> <u>emtricitabine/tenofovir</u> <u>alafenamide fumarate</u> <u>Dolutegravir</u> <u>sodium/rilpivirine</u> <u>hydrochloride</u> <u>Bictegravir</u> <u>sodium/emtricitabine/</u> <u>tenofovir alafenamide</u> <u>fumarate</u> <u>Rilpivirine</u> <u>Rilpivirine hydrochloride</u> <u>Rilpivirine hydrochloride/</u> <u>emtricitabine/tenofovir</u> <u>alafenamide fumarate</u>		blood concentration of these <u>antiviral</u> drugs.
--	--	---	--	--	---